Which patients with inflammatory polyarthritis will ‘fail’ methotrexate?

Young patients who are rheumatoid factor-positive or have high disease activity are most at risk of finding methotrexate (MTX) doesn’t help with their inflammatory polyarthritis, a UK study shows.

The prospective cohort study of 430 patients with early disease prescribed first-line methotrexate showed that a third either changed drugs or added in another drug because methotrexate was not sufficiently efficacious during the average follow-up of nearly four years.

High disease activity at baseline as measured on the DAS-28-CRP(3) scale was associated with early